[Federal Register Volume 81, Number 106 (Thursday, June 2, 2016)]
[Notices]
[Pages 35372-35373]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-12892]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY:  National Institutes of Health.

ACTION:  Notice.

-----------------------------------------------------------------------

SUMMARY:  The inventions listed below are owned by an agency of the 
U.S. Government and are available for licensing in the U.S. in 
accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve 
expeditious commercialization of results of federally-funded research 
and development.

FOR FURTHER INFORMATION CONTACT:  Licensing information may be obtained 
by emailing the indicated licensing contact at the National Heart, 
Lung, and Blood, Office of Technology Transfer and Development Office 
of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, 
MD 20892-2479; telephone: 301-402-5579. A signed Confidential 
Disclosure Agreement may be required to receive any unpublished 
information.

SUPPLEMENTARY INFORMATION:  Technology description follows.

Albumin Binding Immunomodulatory Compositions

    The invention relates to molecules wherein Evan's Blue dye is 
chemically conjugated to CpG Oligonucleotides that elicit anti-tumoral 
or infection fighting immunity. Evans Blue, a symmetric azo dye, has 
high binding affinity to albumin. Albumin binding ability of Evans blue 
is utilized with CpGs and tumor-specific antigens, in order to leverage 
endogenous albumin that increases the safety and the potency of 
molecular vaccines. As such, the molecular entities provided here 
enable efficient delivery and prolonged retention in lymph nodes and 
reduce systemic toxicity of Evans Blue and enhanced the therapeutic 
potency of molecular vaccines.

Potential Commercial Applications:
 Cancer therapeutics
 Infectious disease therapeutics
 Lymph node specificity
 Higher stability/Lower toxicity
Development Stage:
 Early stage


[[Page 35373]]


    Inventors: Xiaoyuan Chen and Guizhi Zhu (both of NIBIB).
    Intellectual Property: HHS Reference No. E-149-2016/0; U.S. 
Provisional Patent Applications 62/331,890 filed May 4, 2016.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
[email protected].

    Dated: May 26, 2016.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2016-12892 Filed 6-1-16; 8:45 am]
 BILLING CODE 4140-01-P